BCRX - バイオクリスト・ファ―マシュ―ティカルズ (BioCryst Pharmaceuticals Inc.) バイオクリスト・ファ―マシュ―ティカルズ

 BCRXのチャート


 BCRXの企業情報

symbol BCRx
会社名 BioCryst Pharmaceuticals Inc (バイオクリスト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バイオクリスト・ファーマシューティカルズ(BioCryst Pharmaceuticals Inc.)はバイオテクノロジー企業である。病気の病因に関与する酵素をブロックする小分子薬の設計、最適化と開発を行う。同社は希少疾患の治療に集中する。同社はX線結晶学、分子構造のコンピュータモデリングと化学技術を利用して細胞生物学を制御する酵素の活性部位特性と三次元的な分子構造の解明に集中する。同社の薬剤候補はRAPIVAB、RAPIACTA、ALPIVAB、PERAMIFLU、Avoralstat、BCX7353、他の第二世代遺伝性血管浮腫(HAE)化合物、GalidesivirとForodesineなどを含む。同社の製品RAPIVABはペラミビルを含む。ALPIVABは静脈内ノイラミニダーゼ阻害剤である。Galidesivirは出血熱ウイルスの治療に向けの広域抗ウイルス(BSAV)研究プログラムである。Forodesineはがん治療薬としてMundipharmaによる開発されたプリンヌクレオシドホスホリラーゼ(PNP)阻害剤である。   バイオクリスト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。疾患の発症を引き起こす酵素を阻害する薬剤の開発に従事。インフルエンザ患者の治療薬ペラミビル、痛風治療薬ウロデシン、血液学的悪性腫瘍の治療薬フォロデシン、遺伝性血管性浮腫(HAE)の治療薬BCX4161などの開発を行う。またエボラウィルスの治療用抗ウィルスの研究を手掛ける。   BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
本社所在地 4505 Emperor Blvd. Suite 200 Durham NC 27703 USA
代表者氏名 Robert A. Ingram ロバートA.イングラム
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 919-859-1302
設立年月日 1986年
市場名 NASDAQ National Market System
ipoyear 1994年
従業員数 85人
url www.biocryst.com
nasdaq_url https://www.nasdaq.com/symbol/bcrx
adr_tso
EBITDA EBITDA(百万ドル) -70.93800
終値(lastsale) 6.79
時価総額(marketcap) 744144753.8
時価総額 時価総額(百万ドル) 745.24070
売上高 売上高(百万ドル) 29.12000
企業価値(EV) 企業価値(EV)(百万ドル) 716.19070
当期純利益 当期純利益(百万ドル) -78.90000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioCryst Pharmaceuticals Inc. revenues increased 31% to $16.5M. Net loss increased 42% to $44.2M. Revenues reflect Collaborative and other research and dev increase from $5.7M to $12.7M. Higher net loss reflects General_Administrative increase from $5.9M to $17.1M (expense) Research and development increase of 21% to $39.5M (expense).

 BCRXのテクニカル分析


 BCRXのニュース

   BioCryst Pharmaceuticals, Inc. (BCRX) Investor Presentation - Slideshow (NASDAQ:BCRX)  2020/09/15 18:56:29 Seeking Alpha
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with this event..
   Key Takeaways From Our Win In BioCryst Pharmaceuticals (BCRX) - Jonathan Faison  2020/06/30 20:01:48 Seeking Alpha
Biocryst Pharmaceuticals is a rare disease player (HAE and Factor D in PNH and other complement mediated diseases), with antiviral kicker (galidesivir) providing optionality.
   Moving Average Crossover Alert: BioCryst Pharmaceuticals  2020/05/18 13:30:00 Zacks Investment Research
BioCryst Pharmaceuticals, Inc. (BCRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards?  2020/04/29 17:17:00 Zacks Investment Research
During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease
   BioCryst Pharmaceuticals (BCRX) Stock Sinks As Market Gains: What You Should Know  2020/04/27 21:50:11 Zacks Investment Research
BioCryst Pharmaceuticals (BCRX) closed at $3.55 in the latest trading session, marking a -0.28% move from the prior day.
   Key Takeaways From Our Win In BioCryst Pharmaceuticals (BCRX) - Jonathan Faison  2020/06/30 20:01:48 Seeking Alpha
Biocryst Pharmaceuticals is a rare disease player (HAE and Factor D in PNH and other complement mediated diseases), with antiviral kicker (galidesivir) providing optionality.
   Moving Average Crossover Alert: BioCryst Pharmaceuticals  2020/05/18 13:30:00 Zacks Investment Research
BioCryst Pharmaceuticals, Inc. (BCRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards?  2020/04/29 17:17:00 Zacks Investment Research
During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease
   BioCryst Pharmaceuticals (BCRX) Stock Sinks As Market Gains: What You Should Know  2020/04/27 21:50:11 Zacks Investment Research
BioCryst Pharmaceuticals (BCRX) closed at $3.55 in the latest trading session, marking a -0.28% move from the prior day.
   Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?  2020/04/27 15:30:11 Zacks Investment Research
Is (BCRX) Outperforming Other Medical Stocks This Year?
   Moving Average Crossover Alert: BioCryst Pharmaceuticals  2020/05/18 13:30:00 Zacks Investment Research
BioCryst Pharmaceuticals, Inc. (BCRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards?  2020/04/29 17:17:00 Zacks Investment Research
During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease
   BioCryst Pharmaceuticals (BCRX) Stock Sinks As Market Gains: What You Should Know  2020/04/27 21:50:11 Zacks Investment Research
BioCryst Pharmaceuticals (BCRX) closed at $3.55 in the latest trading session, marking a -0.28% move from the prior day.
   Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?  2020/04/27 15:30:11 Zacks Investment Research
Is (BCRX) Outperforming Other Medical Stocks This Year?
   Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock?  2020/04/15 13:36:00 Zacks Investment Research
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイオクリスト・ファ―マシュ―ティカルズ BCRX BioCryst Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)